Dulaglutide Mechanism of Action: How Dulaglutide Works | Elicit
Dulaglutide Mechanism of Action
How Dulaglutide (Trulicity) Works: GLP-1 receptor activation increases cAMP and insulin release; it also decreases glucagon secretion and slows gastric emptying.
Last updated:
March 2026
Quick Summary
Dulaglutide (Trulicity) is a GLP-1 receptor agonist used to improve glycemic control in type 2 diabetes. It activates GLP-1 receptors on pancreatic beta cells, increasing intracellular cAMP and promoting insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying, contributing to lower fasting and postprandial glucose levels, and is indicated to reduce MACE risk in appropriate adults with T2DM.
Properties
| Details | |
|---|---|
| Generic Name | Dulaglutide |
| Brand Names | Trulicity |
| Drug Class | GLP-1 receptor agonist (incretin mimetic) |
| Primary Target | Glucagon-like peptide-1 receptor (GLP1R) |
| Approved Indications | Type 2 diabetes mellitus (T2DM), cardiovascular risk reduction (MACE) in adults with T2DM with established cardiovascular disease or multiple cardiovascular risk factors |
| Key Effect | Reduces fasting and postprandial glucose by activating GLP-1 receptors to enhance insulin secretion, decrease glucagon secretion, and slow gastric emptying |
Development History
Dulaglutide originated at Eli Lilly and Company as the program compound LY2189265, engineered to overcome the rapid dipeptidyl peptidase-4 (DPP-4) inactivation that limits native GLP-1 to a circulating half-life of minutes. The molecule fuses two modified GLP-1(7-37) analog peptides to a human IgG4 Fc fragment via flexible glycine-serine linkers,...
Detailed Mechanism of Action
Dulaglutide is engineered as a GLP-1 Fc-fusion pharmacophore that does not enter target cells in the manner of a small molecule but instead distributes systemically after subcutaneous injection, reaching pancreatic islets, gastrointestinal enteric neurons, vagal afferents, and hypothalamic–brainstem circuits via the circulation. Its large molecular format produces a ~59.7 kDa homodimer that resists rapid renal clearance. FcRn-mediated pharmacokinetic extension is the primary mechanism of prolonged exposure...
Clinical Relevance
Approved Indications
Adjunct to diet and exercise for adults with type 2 diabetes (T2DM): Dulaglutide is indicated for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise.
Glycemic control in T2DM: Dulaglutide improves glycemic control as monotherapy and when used with other glucose-lowering agents.
Reduction of major adverse cardiovascular events (REWIND): In REWIND, dulaglutide reduced the incidence of 3-point MACE versus placebo in adults with T2DM with and without established cardiovascular disease.
Key Drug Interactions (Mechanism-Based)
Delayed gastric emptying (effect on oral absorption): Dulaglutide can delay gastric emptying, which may alter absorption kinetics of co-administered oral drugs.
Oral contraceptives timing (≥1 hour): To reduce absorption timing shifts, oral contraceptives are recommended at least 1 hour before GLP-1 receptor agonist dosing.
Warfarin (monitor INR): Concurrent dulaglutide may affect warfarin PK and warrants close INR monitoring, given warfarin’s narrow therapeutic index.
Insulin and sulfonylureas (hypoglycemia risk): Adding dulaglutide to insulin or sulfonylureas increases hypoglycemia risk; dose reductions/adjustments are recommended to avoid events.
Black Box Warnings
Medullary Thyroid Carcinoma (MTC) / MEN2 contraindication: Dulaglutide is contraindicated in patients with a personal or family history of MTC and in those with MEN2.
Pancreatitis precaution: Dulaglutide should not be used in patients with a history of pancreatitis.
Emerging Indications
Neurology
- Alzheimer's Disease and Cognitive Impairment (Phase 3, exploratory): GLP-1 receptor activation reduces neuroinflammation and improves neuronal insulin signaling...
Hepatology
- NAFLD / MASH (Phase 4): GLP-1 receptor agonism reduces hepatic de novo lipogenesis and improves insulin sensitivity...
Clinical Trials of Dulaglutide
| Trial Name | Phase | Design | N Enrolled | Intervention | Indication | Primary Endpoint | Key Result | Status |
|---|---|---|---|---|---|---|---|---|
| AWARD-PEDS (2016-2022) | 3 | randomized, placebo-controlled trial | 154 | Once-weekly dulaglutide 0.75 mg or 1.5 mg vs placebo; in patients aged 10 to 17 years. | Type 2 Diabetes in youth | Change from baseline in A1C at 26 weeks | At 26 weeks, dulaglutide was superior to placebo in improving glycemic control. | Completed |
| ... | ... | ... | ... | ... | ... | ... | ... | ... |
Open Research Questions
What is the mechanism underlying dulaglutide's cardiovascular protection, and does it plateau at current GLP-1 receptor occupancy?
Understanding whether cardioprotection is driven by glycemic improvement...
How does dulaglutide's hepatic activity - including weight-independent suppression of de novo lipogenesis - translate to clinical outcomes in metabolic dysfunction-associated steatotic liver disease?
Liver disease represents an expanding indication for GLP-1 receptor agonists, and distinguishing direct hepatic GLP-1 receptor effects from indirect weight-loss effects is critical for patient selection and combination strategies.